The government has approved the purchase of a coronavirus vaccine from Sanofi Pasteur & GSK



[ad_1]

Along with other countries of the European Union (EU), Lithuania has joined the initiative of the European Commission, according to which Lithuania will be able to buy a vaccine against the coronavirus. Lithuania seeks to diversify the procurement of vaccines among various manufacturers in order to start using an effective and safe vaccine registered by decision of the European Commission as soon as possible.

SAM recalls that Lithuania aims to acquire 70 percent. the population of the country to be vaccinated. According to medical recommendations, this number of vaccines is necessary for the development of herd immunity.

At present, Lithuania has decided to purchase vaccines from the pharmaceutical companies Astra Zeneca and Janssen Pharmaceutica NV.

So far, it has been decided to buy the coronavirus vaccine from three companies, but the government will also consider buying the vaccine from other manufacturers.

It will allocate 20 thousand. euros for delivery of the vaccine to Lithuania

On Wednesday, the Cabinet of Ministers approved the proposal of the Ministry of Health (SAM) to acquire the vaccine transport services of the pharmaceutical AstraZeneca and allocate 20 thousand. euros to purchase this service.

Together with other European Union countries, participating in the joint purchase of the vaccine organized by the European Commission, Lithuania has already decided to buy 1.86 million from AstraZeneca. doses of the vaccine as soon as the vaccine is made.

Advance purchase agreements have also been entered into with the pharmaceutical companies Janssen Pharmaceutica NV and Sanofi-GSK.

SAM recalls that Lithuania aims to acquire 70 percent. population of the country to vaccinate, as well as diversify vaccine purchases among various manufacturers. According to medical recommendations, this number of vaccines is necessary for the development of herd immunity.

The vaccines will not be marketed until their clinical trials have been completed.

No part of this publication may be reproduced without the written permission of ELTA.



[ad_2]